Anti-cytokeratin Pan / Ms. / monoclonal / C2562 / #060M4859
#039K4825 / Mixture of several monoclonal cytokeratin clones (clone C-11+PCK-26+CY-90+KS-1A3+M20+A53-B/A2) / 1:100 / Sigma-Aldrich
Anti-cytokeratin 4 / Rb. / polyclonal / ab51600 / #791954 / Synthetic peptide corresponding to residues near the N terminal of human cytokeratin 4 / Antigen mol wt 57 kDa (1) / 1:100 / Abcam
Anti-cytokeratin 5 / Rb. / polyclonal / ab53121 / Synthetic peptide derived from human cytokeratin 5 / Antigen mol wt 62 kDa (1) / 1:100 / Abcam
Anti-cytokeratin 7 / Ms. / monoclonal / ab9021 / #858182 / Human Cytokeratin 7 bladder carcinoma cell line T24 / Antigen mol wt 54 kDa (1) / 1:100 / Abcam
Anti-cytokeratin 8 / Ck. / polyclonal / ab14053 / #746248
#Gr6612-4 / Recombinant fragment, corresponding to amino acids 391-483 of Human cytokeratin 8 / Antigen mol wt 54 kDa (1, see study Fig. S1) / 1:100 / Abcam
Anti-vimentin / Ms. / monoclonal / V6389 / #041M4750 / Pig eye lens vimentin / Antigen mol wt ~58kDa (1, 2, 3, 4, 5, see study Fig. S1) / 1:100 / Sigma-Aldrich
Anti-E-cadherin / Rb. / polyclonal / ab53033 / #746935 / Synthetic peptide derived from human E-cadherin / Antigen mol wt 97 kDa (1, 6, see study Fig. S1) / 1:100 / Abcam
Anti-β-catenin / Rb. / monoclonal / ab32572 / #Gr33506-1 / Synthetic peptide corresponding to residues near N terminus of human β-catenin / Antigen mol wt 120 kDa (1, 7, see study Fig. S1) / 1:100 / Abcam
Anti-myosin IV / Rb. / monoclonal / M5187 / #079K4839 / Synthetic peptide corresponding to amino acids 291-302 of human myosin VI / Antigen mol wt ~150kDa (1) / 1:150 / Sigma-Aldrich
Anti-p27 kip1 / Ms. / monoclonal / P2092 / #027K4831 / Recombinant rodent p27Kip1 / Antigen mol wt 27kDa (1) / 1:100 / Sigma-Aldrich
Table S1. Specifications of different primary antibodies used in the study